Evidence map›Paper›PMID 33660388›Full record

ArticleAmerican journal of reproductive immunology (New York, N.Y. : 1989)2021

Prolactin modifies the in vitro LPS-induced chemotactic capabilities in human fetal membranes at the term of gestation.

Estefanía Núñez-Sánchez, María Del Pilar Flores-Espinosa, Ismael Mancilla-Herrera, Leticia González, José Cisneros, Andrea Olmos-Ortiz, Braulio Quesada-Reyna, Martha Granados-Cepeda, Veronica Zaga-Clavellina

Open access · bronzeAbstract read
In one paragraph

Article in American journal of reproductive immunology (New York, N.Y. : 1989), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Estefanía Núñez-SánchezDepartamento de Inmunobioquímica, Instituto Nacional de Perinatología "Isidro Espinosa de los Reyes", Ciudad de México, México.
María Del Pilar Flores-EspinosaDepartamento de Inmunobioquímica, Instituto Nacional de Perinatología "Isidro Espinosa de los Reyes", Ciudad de México, México.ORCID 0000-0003-2140-3629
Ismael Mancilla-HerreraDepartamento de Infectología e Inmunología, Instituto Nacional de Perinatología "Isidro Espinosa de los Reyes", Ciudad de México, México.ORCID 0000-0001-8195-8082
Leticia GonzálezDepartamento de Inmunobioquímica, Instituto Nacional de Perinatología "Isidro Espinosa de los Reyes", Ciudad de México, México.ORCID 0000-0001-9150-0569
José CisnerosLaboratorio de Biopatología Pulmonar, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Ciudad de México, México.ORCID 0000-0002-4592-4464
Andrea Olmos-OrtizDepartamento de Inmunobioquímica, Instituto Nacional de Perinatología "Isidro Espinosa de los Reyes", Ciudad de México, México.ORCID 0000-0002-5456-9695
Braulio Quesada-ReynaDivisión de Gineco-Obstetricia, UMAE Hospital de Gineco-Obstetricia No. 4 "Luis Castelazo Ayala" IMSS, Ciudad de México, México.
Martha Granados-CepedaDepartamento de Neonatología, Instituto Nacional de Perinatología "Isidro Espinosa de los Reyes", Ciudad de México, México.
Veronica Zaga-ClavellinaDepartamento de Fisiología y Desarrollo Celular, Instituto Nacional de Perinatología "Isidro Espinosa de los Reyes", Ciudad de México, México.ORCID 0000-0002-3365-2932
Instituto Nacional de Enfermedades Respiratorias · MXMexican Social Security Institute · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

problemImmune responses of fetal membranes involve the production of chemoattractant mediators causing infiltration of maternal and fetal leukocytes, intrauterine inflammation and potentially the disruption of maternal-fetal tolerance. Prolactin (PRL) has deep immunoregulatory effects in the fetal-maternal interface. We aimed to test the in vitro PRL effect upon chemotactic capacities of human fetal membranes. METHOD OF STUDY: Fetal membranes and umbilical cord blood were collected from healthy non-laboring caesarean deliveries at term. Fetal membranes were cultured in Transwell® frames to mimic the barrier function between choriodecidual and amniotic sides. Tissues were treated with PRL, Lipopolysaccharide (LPS), or both simultaneously. Then, RANTES, MCP-1, MIP-1α, IP-10, and PECAM-1 were quantified in a conditioned medium by choriodecidual or amniotic sides. The chemotaxis of subsets of migrating mononuclear cells from umbilical cord blood was evaluated in a Boyden Chamber in response to the conditioned medium by both sides.

resultsLipopolysaccharide stimulates the production of RANTES, MCP-1, MIP-1α, and PECAM-1 in choriodecidua, while MIP-1α and PECAM-1 only increase in amnion. PRL decrease RANTES, MCP-1, and MIP-1 only in choriodecidua, but PECAM-1 was decreased mainly in amnion. The leukocyte migration was regulated significantly in response to the conditioned medium by the amnion, increase in the conditioned medium after LPS treatment, contrary with, the leukocyte migration decreased in a significant manner in response to conditioned medium after PRL and LPS-PRL co-treatment. Finally, T cells were the most responsive subset of cells.

conclusionsProlactin modified in a tissue-specific manner the chemotactic factor and the leukocyte migration differentially in fetal membranes.

Indexed as

AdultChemokinesChemotaxisExtraembryonic MembranesFemaleFetal BloodHumansLeukocytes, MononuclearLipopolysaccharidesPregnancyProlactinChemokinesLipopolysaccharidesProlactinamnionleukocytesLPSmigrationprolactinT cells

Identifiers

PMID33660388
PMCPMC8365646
OpenAlexW3134938713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.